(0)
7MBq dose of Radspherin
determined to be safe, and approved by the SMC as the recommended clinical dose for repeated injection and expansion cohorts of RAD-18-002 study
Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that the Safety Monitoring Committee for the RAD-18-002 clinical trial has concluded that the 7 MBq dose of Radspherin to be safe and has approved initiation of the repeated injection and expansion cohorts of the ongoing RAD-18-002 Phase 1 study in colorectal cancer patients suffering from peritoneal carcinomatosis. Radspherin, an a-emitting radionuclide therapy designed for treatment of metastatic cancers in body cavities, is also being evaluated in an ongoing Phase 1 study in ovarian cancer patients with peritoneal carcinomatosis.